Last reviewed · How we verify
CD34-positive cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
CD34-positive cells (CD34-positive cells) — Losordo, Douglas, M.D..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CD34-positive cells TARGET | CD34-positive cells | Losordo, Douglas, M.D. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CD34-positive cells CI watch — RSS
- CD34-positive cells CI watch — Atom
- CD34-positive cells CI watch — JSON
- CD34-positive cells alone — RSS
Cite this brief
Drug Landscape (2026). CD34-positive cells — Competitive Intelligence Brief. https://druglandscape.com/ci/cd34-positive-cells. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab